Table 1.

Representative NPs in Clinical Trials for Treatment of CRC

Name	Indication	Intervention/Treatment	Stage	NCT Number
Cetuximab nanoparticles (p.o).	Colon Cancer Colo-rectal Cancer	Drug: Cetuximab nanoparticles Drug: Oral approved anticancer drug	Phase 1 (Unknown)	NCT03774680
Nanoparticle Paclitaxel (i.p).	Peritoneal Neoplasms	Drug: nanoparticulate paclitaxel	Phase 1 (Completed)	NCT00666991
Aguix Gadolinium-Based Nanoparticles (radiotherapy)	Brain Metastases	Radiation: Stereotactic Radiation Drug: AGuIX gadolinium-based nanoparticles Other: Placebo	Phase 2 (Recruiting)	NCT04899908
AZD4635 (p.o).	Advanced Solid Malignancies	Drug: AZD4635 Drug: Durvalumab Drug: Abiraterone Acetate	Phase 1 (Completed)	NCT02740985
CALAA-01 (i.v).93–96	Cancer Solid Tumor	Drug: CALAA-01	Phase 1 (Terminated)	NCT00689065
TKM 080301 (hepatic intra-arterial administration)97–99	Primary or Secondary Liver Cancer	Drug: TKM-080301	Phase 1 (Completed)	NCT01437007
9-ING-41 (i.v).	Advanced Cancers	Drug: 9-ING-41 Drug: Gemcitabine - 21 day cycle Drug: Doxorubicin. Drug: Lomustine Drug: Carboplatin. Drug: Nab paclitaxel. Drug: Paclitaxel. Drug: Gemcitabine - 28 day cycle Drug: Irinotecan	Phase 2 (Recruiting)	NCT03678883
Nal-IRI(i.v).	Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer	Drug: Fluorouracil Drug: Irinotecan Sucrosofate Other: Laboratory Biomarker Analysis Drug: Leucovorin Calcium Drug: Rucaparib	Phase ½ (Active, not recruiting)	NCT03337087
Nanoparticle Paclitaxel (i.p).	Peritoneal Neoplasms	Drug: nanoparticulate paclitaxel	Phase 1 (Completed)	NCT00666991

Notes: Updated on 01/24/2024. All clinical trials listed in this table are based on ClinicalTrials.gov.

Abbreviations: P.O., oral; i.p., intraperitoneal; i.v., intravenous; nal-IRI, liposomal irinotecan.